BiotechTube

Odevixibat

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alagille Syndrome

Conditions

Alagille Syndrome

Trial Timeline

Sep 3, 2021 → Dec 31, 2026

NCT ID
NCT05035030

About Odevixibat

Odevixibat is a phase 3 stage product being developed by Ipsen for Alagille Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05035030. Target conditions include Alagille Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT04483531Pre-clinicalCompleted
NCT05426733Phase 3Recruiting
NCT05035030Phase 3Recruiting

Competing Products

9 competing products in Alagille Syndrome

See all competitors
ProductCompanyStageHype Score
Odevixibat + PlaceboIpsenPhase 3
74
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
maralixibatMirum PharmaceuticalsPre-clinical
20
Livmarli + LivmarliMirum PharmaceuticalsPre-clinical
20
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
LUM001 (Maralixibat) + PlaceboMirum PharmaceuticalsPhase 2
49
Livmarli Oral ProductMirum PharmaceuticalsApproved
82
LUM001 + PlaceboMirum PharmaceuticalsPhase 2
49
LUM001 + PlaceboMirum PharmaceuticalsPhase 2
49

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved
82
lanreotide acetateApproved
82
Tigan® + PlaceboApproved
82
Diosmectite (Smecta®)Approved
82
lanreotide (Autogel formulation)Approved
82